Financial Performance - The company's operating revenue for 2022 was approximately ¥3.41 billion, representing a 24.82% increase compared to ¥2.73 billion in 2021[27]. - The net profit attributable to shareholders for 2022 surged to approximately ¥305.53 million, a remarkable increase of 978.35% from ¥28.33 million in 2021[27]. - The net profit after deducting non-recurring gains and losses reached approximately ¥291.92 million, up 2,895.04% from ¥9.75 million in 2021[27]. - The net cash flow from operating activities for 2022 was approximately ¥150.99 million, a significant turnaround from a negative cash flow of ¥68.96 million in 2021, marking a 318.95% improvement[27]. - The basic earnings per share for 2022 increased to ¥0.29, reflecting an 866.67% rise from ¥0.03 in 2021[27]. - The total assets at the end of 2022 were approximately ¥5.70 billion, a 1.75% increase from ¥5.60 billion at the end of 2021[27]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥3.37 billion, up 12.61% from ¥2.99 billion at the end of 2021[27]. - The total revenue for 2022 reached ¥3,411,357,924.54, representing a year-on-year increase of 24.82% compared to ¥2,732,994,049.94 in 2021[69]. - The pharmaceutical and chemical segment generated ¥3,304,949,711.30, accounting for 96.88% of total revenue, with a year-on-year growth of 24.50%[69]. - The revenue from pharmaceutical products was ¥2,047,916,359.21, which is 60.03% of total revenue, showing a growth of 20.38% from the previous year[69]. - The special chemicals segment reported revenue of ¥1,257,033,352.09, marking a significant increase of 31.86% year-on-year[69]. Dividend and Profit Distribution - Brother Technology reported a cash dividend of 1 RMB per 10 shares for all shareholders, with no stock bonus[4]. - The company has established a clear cash dividend policy that complies with regulations and ensures transparency in decision-making processes[186]. - The company reported a cash dividend of 1.00 yuan per 10 shares (including tax), with a total distributable profit of 613,325,045.91 yuan, representing 100% of the profit distribution[187]. - The company has not proposed any stock dividends or capital reserve transfers, focusing solely on cash dividends for the reporting period[189]. Risk Management and Compliance - The company emphasized the importance of risk awareness regarding future plans and development strategies, highlighting potential operational risks and countermeasures[4]. - Brother Technology has a comprehensive risk management strategy outlined in the management discussion and analysis section of the report[4]. - The company faces risks from macroeconomic uncertainties, industry competition, raw material price fluctuations, and exchange rate volatility, and is implementing strategies to mitigate these risks[134]. - The company maintains compliance with various regulatory requirements, holding multiple production licenses and safety certifications valid until 2026 and beyond[48]. Corporate Governance - The annual report was approved by the board of directors, ensuring the accuracy and completeness of the financial statements[4]. - The company has established a complete independent research, production, procurement, and sales system, ensuring no reliance on the controlling shareholder[152]. - The company maintains a clear separation of assets, with independent ownership of land, factories, and equipment related to its main business[154]. - The company has an independent financial department with a dedicated financial management team, ensuring independent financial decision-making[156]. - The company emphasizes social responsibility and actively collaborates with stakeholders to promote sustainable development[150]. - The company's governance structure complies with relevant laws and regulations, with no significant discrepancies reported[150]. Research and Development - The company has a strong emphasis on research and development, particularly in organic chemistry and materials science, led by its independent director Yu Biao[166]. - The company has 20 products in the research pipeline, with 2 products already submitted for domestic drug registration[62]. - The company has established a three-tiered technology innovation mechanism, including a group research institute and various R&D centers, enhancing its technical capabilities in vitamin and leather chemical products[51]. - The company is committed to optimizing its R&D team and enhancing external resource integration to boost its technological competitiveness[133]. Market and Industry Trends - The company operates in the vitamin, flavor and fragrance, and pharmaceutical sectors, with a focus on long-term development and market expansion[36][37][38]. - The global flavor and fragrance market is projected to grow at a rate of 3.6% annually from 2021 to 2026, with significant growth expected in emerging markets like China[37]. - The global active pharmaceutical ingredient (API) market is projected to reach $245.2 billion by 2024, with a CAGR of 6.12% from 2017 to 2024[39]. - The CMO market in China is expected to maintain a CAGR of over 18% from 2020 to 2025, with a market size exceeding 120 billion yuan by 2025[41]. Operational Efficiency - The company has achieved industrial-scale production for key products like Vitamin K3 and Vitamin B1, indicating strong operational capabilities[45]. - The company holds several patents for its products, including ZL201310135494.X for Vitamin K3, showcasing its commitment to innovation and proprietary technology[45]. - The company has a total of 8,000 tons of iodine contrast agent raw material and intermediate project under construction, with a first phase capacity of 1,150 tons[48]. - The company has a total of 50,000 tons of inorganic chromium powder project currently in the construction phase[46]. Employee and Management Structure - The company has a total of 2,947 employees, with 283 in the parent company and 2,364 in major subsidiaries[181]. - The company has implemented a training plan aimed at improving employee skills and aligning with strategic goals, including specific programs for different employee levels[184]. - The company has a diverse customer base across various industries, effectively reducing operational risks associated with customer concentration[52]. - The company has developed a robust management team with strong technical and management capabilities, ensuring effective industry trend analysis and strategic planning[53]. Strategic Initiatives - The company is focusing on the emerging energy storage industry, particularly in the development of iron-chromium flow battery-related products[59]. - The company is actively pursuing strategic partnerships with suppliers to manage raw material price volatility and enhance cost control[134]. - The company aims to transition from a "manufacturing" to a "manufacturing + service" model to better meet market demands and create value for customers[125]. - The company is committed to continuous technological innovation and process optimization, maintaining a high level of automation in its production processes[46].

Group 1: Vitamin B1 Overview - Vitamin B1 is primarily used in feed, food, and pharmaceutical industries. The main competitors are Hubei Huazhong and Jiangxi Tianxin. Current product prices have increased compared to the beginning of the year [1]. Group 2: Vitamin B3 Overview - The global market capacity for Vitamin B3 is relatively large. Since the beginning of the year, raw material prices have decreased, leading to a slight increase in product prices and an improvement in gross profit margins [2]. Group 3: Vitamin K3 and Chrome Tanning Agent Overview - The company is the largest producer of Vitamin K3 globally, with a production capacity of 3,000 tons. Since 2013, the gross profit margin for K3 has remained stable due to low raw material prices. The chrome tanning agent industry is currently undergoing a reshuffle due to high raw material prices and environmental pressures, impacting sales in the short term [2]. Group 4: Chrome Waste Sludge Utilization Project - The chrome waste sludge cleaning and comprehensive utilization project is currently in a pilot phase in Haining, collaborating with local tanning enterprises. Revenue sources include sludge treatment fees and reduced raw material costs. The focus for 2014 is on market promotion [2]. Group 5: Raw Material Market Situation - The price of the main raw material, sodium aluminate, experienced a slight increase in the first half of the year. In the second half, with the completion of technical upgrades by related production enterprises, the supply of sodium aluminate is expected to become more abundant [2].

Group 1: Vitamin Overview - Vitamin consumption structure is stable across feed, pharmaceuticals, cosmetics, and food and beverage sectors, with developed countries having higher addition ratios compared to developing countries, which show greater growth potential [1][2] - Global demand for Vitamin B1 is between 7,500 to 8,000 tons, primarily used in feed, food, and pharmaceuticals; competitors include Hubei Huazhong and Jiangxi Tianxin [2] - The company is the largest global producer of Vitamin K3, with advanced production facilities ensuring high product yield and quality, and stable market demand due to low addition ratios in feed [2] - The global market capacity for Vitamin B3 is approximately 50,000 to 60,000 tons, with the company ranking among the top four in market share; expected economic benefits from capacity release in 2014 [2] Group 2: Leather Chemicals Project - The company's leather additives are non-standard products with a wide variety and significant market potential, maintaining stable profits and being a key development focus [2] - The company aims for import substitution in high-end leather additives, supported by its own R&D center and a professional technical service team providing comprehensive process solutions [3]

Group 1: Vitamin B1 Overview - Vitamin B1 is primarily used in feed, food, and pharmaceutical industries, with a global demand of approximately 7,500-8,000 tons [2] - The company is currently in a phase of halting external quotations for Vitamin B1 [2] Group 2: Vitamin K3 Overview - The company is the largest global producer of Vitamin K3, with a production capacity of 3,000 tons [3] - The production facility is equipped with the most advanced technology, maintaining top-tier product yield, quality, and waste discharge levels [3] - The combined gross profit margin for Vitamin K3 and chromium tanning agents has improved compared to the same period last year [3] Group 3: Vitamin B3 Overview - The global market capacity for Vitamin B3 is estimated at 50,000-60,000 tons, with the company ranking among the top four in market share [3] - Raw material prices for Vitamin B3 have decreased compared to last year, while product prices have seen a slight increase, leading to improved gross margins due to economies of scale [3] Group 4: Leather Chemicals Project Overview - The company's leather additives are non-standard products with a wide variety and significant market potential, providing stable profits [3] - The domestic market for mid-to-high-end leather additives is largely reliant on imports [3] Group 5: Jiangxi Industrial Park Future Planning - The first phase of the Jiangxi project is planned for 800 acres, focusing on projects related to the company's main business or with similar customer bases [3] - The company has sufficient project reserves, but specific details are not disclosed and will be announced in future communications [3]

附件二：投资者关系活动记录表格式 编号：2015-003 证券代码： 002562 证券简称：兄弟科技 兄弟科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------|-----------------------------|----------------------------------------------------------| | | | | | 投资者关系 | □ 特定对象调研 | □ 分析师会议 | | 活动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | ■ 现场调研 | | | | □ 其他 | | | 参与单位名 | 西南证券股份有限公司 张汪强 | | | 称及人员姓 | | 上海荣正投资咨询有限公司 曾国鑫 鲁 红 | | 名 | | 北京宏道投资管理有限公司 季 巍 | | | | 浙江首发创业投资有限公司 丁谢峰 | | | 上海德汇集团有限公司 潘学诗 | | | | 个人投资者 孙荣昌 | | | 时间 | 2015 年 8 月 5 日 | | | 地点 | 证券投资部会议 ...

Group 1: Investor Relations Activities - The investor relations activity was categorized as "Other" (Investor Reception Day) [2] - Participants included representatives from Jiuren Capital and individual investors [2] - The meeting took place on April 16, 2015, at Haining Pidu Jinjiang Hotel [2] Group 2: Vitamin Market Insights - The global vitamin market is experiencing stable demand with an annual growth rate of approximately 3%-5% [3] - The price of Vitamin K3 was increased by about 35% in the first quarter due to rising raw material costs [3] - The total global demand for Vitamin B5 in 2013 was approximately 21,000 tons, with significant growth expected in developing countries [3] Group 3: Project Development Updates - The company has acquired 700 acres of industrial land, with construction for the Vitamin B3 and B5 projects set to begin in the second quarter of 2015 [3] - The first phase of the project is expected to complete construction and enter trial production by the third quarter of 2016 [3] Group 4: Leather Chemicals Market - The leather industry has faced challenges due to high raw material prices and environmental pressures, impacting sales of leather chemicals [4] - The company has established a professional application research team to provide solutions aimed at reducing costs and improving product quality [4] - Marketing networks have been successfully established in South America, North Africa, and Southeast Asia, yielding positive sales results [4] Group 5: Future Development Directions - The company plans to focus on its core business while pursuing both organic growth and mergers/acquisitions [4] - There will be increased investment in high-value-added leather auxiliary products and further development of feed additives, food additives, and pharmaceutical raw materials [4] Group 6: Arbitration Situation - The company has executed part of the equity transfer prepayment, with ongoing execution of subsequent payments [4] - Although the execution speed is slow, the current situation indicates a high level of assurance for execution [4]

附件二：投资者关系活动 证券代码：002562 证券简称：兄弟科技 兄弟科技股份有限公司投资者关系活动记录表 编号：2015-005 | --- | --- | --- | |----------------|-------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | ■ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 国泰基金 叶 烽 | | | 人员姓名 | 国海证券 司马湫 | | | | 洛卡商务咨询 苗 壮 | | | 时间 | 证券投资部会议室 | | | 地点 | 2015 年 11 月 6 日 | | | 上市公司接待人 | 董事会秘书 钱柳华 | | | 员姓名 | 董事会秘书助理 沈 洁 | | | 投资者关系活动 | | 调研公司发展和行业情况（以调研机 ...

Group 1: Investor Relations Activities - The investor relations activity included a site visit with participation from various financial institutions such as Guosen Securities and Tianhong Asset Management [2] - The meeting took place in October 2015 at the company's securities investment department meeting room [2] Group 2: Vitamin Market Situation - The company has achieved full capacity operation for its "annual production of 5,000 tons of Vitamin B3" project [3] - The "annual production of 13,000 tons of Vitamin B3 and 20,000 tons of 3-cyanopyridine construction project" aims to address production scale limitations and enhance market competitiveness [3] - The sales promotion of pharmaceutical-grade Vitamin B1 is progressing smoothly, with a stable competitive landscape in the market [3] Group 3: Leather Chemicals Market Situation - The leather industry in China has been undergoing environmental upgrades and industry consolidation, with signs of industrial transfer in the upstream processes [3] - The company has launched higher value-added coating agent products in the leather additives sector, which is expected to improve overall profitability [3] - The qualification certificate for the chromium-containing waste comprehensive utilization project was obtained in the first half of the year, and market promotion efforts are actively underway [3] Group 4: Project Construction Progress - The company officially started the construction of projects in the second quarter of the year, including Vitamin B3, Vitamin B5, and cogeneration projects [3] - The cogeneration project is expected to complete construction and begin trial production in the third quarter of 2016, providing centralized heating for the Qishan Industrial Park [3] Group 5: Legal Matters - The company is actively advancing the arbitration situation with Zhonghua Chemical and has executed part of the equity transfer prepayment at the beginning of the year [4]